SRR1362219
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.512
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.253
- KRAS_SIGNALING_DN+0.211
- SPERMATOGENESIS+0.193
- HEDGEHOG_SIGNALING+0.181
- PANCREAS_BETA_CELLS+0.166
- PROTEIN_SECRETION+0.125
- PI3K_AKT_MTOR_SIGNALING+0.087
- FATTY_ACID_METABOLISM+0.081
- MYC_TARGETS_V2+0.076
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.635
- INTERFERON_GAMMA_RESPONSE-0.572
- IL6_JAK_STAT3_SIGNALING-0.528
- NOTCH_SIGNALING-0.488
- ALLOGRAFT_REJECTION-0.485
- INFLAMMATORY_RESPONSE-0.467
- TNFA_SIGNALING_VIA_NFKB-0.463
- TGF_BETA_SIGNALING-0.433
- ANGIOGENESIS-0.386
- COAGULATION-0.382
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1386708 | GTEX | — | 0.976 |
| 2 | SRR1408208 | GTEX | — | 0.975 |
| 3 | SRR1360563 | GTEX | — | 0.971 |
| 4 | SRR1315970 | GTEX | — | 0.970 |
| 5 | SRR662233 | GTEX | — | 0.970 |
| 6 | SRR821626 | GTEX | — | 0.970 |
| 7 | SRR1311086 | GTEX | — | 0.970 |
| 8 | SRR1328895 | GTEX | — | 0.969 |
| 9 | SRR1455925 | GTEX | — | 0.960 |
| 10 | SRR1416477 | GTEX | — | 0.960 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.512 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.253 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.211 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.193 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.181 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.166 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.125 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.087 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.081 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.076 | Idelalisib | — uncovered |
| PEROXISOME | 0.022 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.021 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.017 | Idelalisib | — uncovered |
| MYOGENESIS | 0.006 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.003 | Temsirolimus | — uncovered |